Detalhe da pesquisa
1.
Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology.
Ann Rheum Dis
; 2024 May 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38740438
2.
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.
Rheumatology (Oxford)
; 61(12): 4905-4909, 2022 11 28.
Artigo
Inglês
| MEDLINE | ID: mdl-35266512
3.
Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.
Rheumatology (Oxford)
; 60(8): 3679-3688, 2021 08 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33432358
4.
Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
Rheumatology (Oxford)
; 59(10): 2838-2846, 2020 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32065634
5.
Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus.
Rheumatology (Oxford)
; 58(2): 304-312, 2019 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30265343
6.
Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status.
Ann Rheum Dis
; 77(10): 1432-1439, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29929956
7.
Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Ann Rheum Dis
; 76(11): 1829-1836, 2017 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-28684557
8.
Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group.
Rheumatology (Oxford)
; 56(6): 882-895, 2017 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27940590
9.
Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
Rheumatology (Oxford)
; 56(8): 1348-1357, 2017 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28444364
10.
The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review.
Rheumatology (Oxford)
; 55(3): 485-94, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26447163
11.
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.
Ann Rheum Dis
; 74(9): 1734-8, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25854586
12.
B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.
Curr Rheumatol Rep
; 17(10): 65, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26290110
13.
Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force.
RMD Open
; 10(2)2024 Apr 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38580348
14.
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
Lancet Rheumatol
; 5(2): e88-e98, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36712951
15.
Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope.
Rheumatol Adv Pract
; 7(3): rkad093, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38058676
16.
Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome.
ACR Open Rheumatol
; 4(8): 689-699, 2022 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-35666029
17.
Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
EBioMedicine
; 86: 104343, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36371989
18.
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.
Front Immunol
; 12: 803175, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-35095887
19.
Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab.
Front Med (Lausanne)
; 7: 498, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32984378
20.
Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity.
Nat Commun
; 11(1): 6149, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33262343